Drug ads must now show you the price—a first step toward transparency

What it does

This bill requires pharmaceutical manufacturers to disclose the wholesale acquisition cost (list price) of prescription drugs in direct-to-consumer advertisements, effective July 1, 2026. The disclosure must appear in all ads for drugs covered by Medicare or Medicaid, except those costing less than $35 for a 30-day supply. Manufacturers who fail to comply face civil penalties up to $100,000 per violation.

Why we flagged it

The bill's core mechanism is a straightforward disclosure requirement—manufacturers must show list prices in ads. It is not a price-control measure, a subsidy, or a deregulation; it is a transparency obligation that shifts information asymmetry in favor of consumers.

What the text implies

• The $35 exemption threshold may create a perverse incentive for manufacturers to keep list prices just below $35 to avoid disclosure, even if actual out-of-pocket costs are higher due to insurance structures.
• Disclosure of wholesale acquisition cost (WAC) does not reflect actual patient out-of-pocket costs, which vary by insurance plan, deductible status, and copay structure. Patients may still be confused about what they will actually pay.
• The bill applies only to drugs covered by Medicare/Medicaid and advertised directly to consumers—a narrow slice of the pharmaceutical market. Drugs advertised only to physicians or not covered by federal programs are exempt.
• Manufacturers may respond by reducing direct-to-consumer advertising for expensive drugs, shifting marketing to physicians and reducing consumer awareness of treatment options, though this may also reduce inappropriate demand inflation.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain access to drug pricing information at the point of advertising, enabling more informed purchasing decisions and potentially reducing wasteful spending on expensive alternatives when cheaper options exist. The bill does not restrict access to medications, impose new costs on patients, or shield any party from liability—it simply mandates transparency that currently exists only behind paywalls or in specialized databases.

Named in the bill

Department of Health and Human Services (HHS), Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), Medicare, Medicaid, Pharmaceutical manufacturers, Biological product manufacturers

Where it stands

8 cosponsors: 4 Democrats, 4 Republicans.

• Jun 5, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jun 5, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 6 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $7,070,000 in lobbying spend. A filing names 26 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

David Taylor, the sponsor, reported $453,000 in PAC receipts in the 2026 cycle.

• CVS Health (and Subsidiaries) — $3,570,000 on 1 filing
• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
• American Society of Health-system Pharmacists — $260,000 on 1 filing
• The Campaign for Sustainable Rx Pricing — $180,000 on 2 filings
• Campaign for Sustainable Drug Pricing (csrxp) — $50,000 on 1 filing

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.